Annexin Pharmaceuticals has published its report for the third quarter of 2025, a period marked by participation in several international conferences, which has strengthened the company's position internationally in ophthalmology. The company also received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to start a new phase IIa clinical trial and expects to treat the first patient shortly.
Read the article at biostock.se:
https://biostock.se/en/2025/10/annexins-q3-etablering-av-medical-advisory-board-och-fokus-pa-oftalmologi/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/